Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of F17464 in acute exacerbation of schizophrenia
2013-005451-32Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing F17464 40 mg/day with Placebo (2 arms). Primary endpoint: Primary efficacy parameter. Started May 2014; status: completed.
02
Drugs
F17464
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2013-005451-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005451-32.